Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CALVARUSO, Vincenza
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.253
EU - Europa 2.437
AS - Asia 675
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 9
AF - Africa 8
SA - Sud America 7
Totale 12.399
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.221
IT - Italia 948
CN - Cina 547
FI - Finlandia 294
UA - Ucraina 255
DE - Germania 195
IE - Irlanda 185
GB - Regno Unito 179
RU - Federazione Russa 117
SE - Svezia 82
RO - Romania 48
FR - Francia 46
KR - Corea 37
BE - Belgio 29
IN - India 25
CA - Canada 21
HK - Hong Kong 17
CH - Svizzera 13
IR - Iran 12
MX - Messico 11
NL - Olanda 11
GR - Grecia 8
JP - Giappone 8
EU - Europa 7
TR - Turchia 7
AU - Australia 6
BR - Brasile 5
EG - Egitto 5
TW - Taiwan 5
AT - Austria 4
ES - Italia 4
NZ - Nuova Zelanda 3
PL - Polonia 3
SG - Singapore 3
UZ - Uzbekistan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
EE - Estonia 2
IL - Israele 2
MD - Moldavia 2
PK - Pakistan 2
RS - Serbia 2
VN - Vietnam 2
AF - Afghanistan, Repubblica islamica di 1
AR - Argentina 1
BG - Bulgaria 1
BY - Bielorussia 1
CM - Camerun 1
EC - Ecuador 1
GH - Ghana 1
HR - Croazia 1
ID - Indonesia 1
MY - Malesia 1
NO - Norvegia 1
PT - Portogallo 1
SA - Arabia Saudita 1
SI - Slovenia 1
TG - Togo 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 12.399
Salva come PNG Salva come JPEG
Città #
Fairfield 1.687
Ashburn 1.004
Woodbridge 806
Houston 682
Seattle 660
Chandler 635
Wilmington 633
Cambridge 583
Ann Arbor 381
Medford 227
Palermo 197
Altamura 191
Dublin 185
Des Moines 143
Princeton 142
Lawrence 133
Nanjing 132
Jacksonville 120
San Diego 101
New York 71
Dearborn 68
Boardman 59
Beijing 57
Tulsa 53
Ludwigshafen am Rhein 48
Shenyang 48
London 44
Hebei 38
Nanchang 35
Jinan 31
Changsha 30
Milan 30
Brussels 29
San Paolo di Civitate 29
Tianjin 28
Jiaxing 27
Phoenix 25
Saint Petersburg 25
Redwood City 24
Ningbo 22
Falls Church 20
Seongnam 20
Los Angeles 17
Rome 17
Zhengzhou 15
Ottawa 14
Venice 14
Helsinki 13
Hangzhou 12
Orange 12
Hounslow 11
Kumar 11
Bremen 10
Foggia 10
Taizhou 10
Auburn Hills 9
Tehran 9
Central 8
Chicago 8
Guangzhou 8
Cuauhtémoc 7
Seoul 7
Catania 6
Hong Kong 6
Kilburn 6
Kunming 6
Messina 6
Napoli 6
Norwalk 6
Piacenza 6
Pune 6
Verona 6
Aachen 5
Augusta 5
Cagliari 5
Chiswick 5
Hefei 5
Moscow 5
Munich 5
Nürnberg 5
Salerno 5
San Mateo 5
Taipei 5
Taiyuan 5
Tappahannock 5
Vicopisano 5
Bari 4
Castelbuono 4
Den Haag 4
Edinburgh 4
Fuzhou 4
Haikou 4
Indiana 4
Izmir 4
Kiev 4
Lanzhou 4
Lappeenranta 4
Lissone 4
Padova 4
Perugia 4
Totale 9.911
Salva come PNG Salva come JPEG
Nome #
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis 190
Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis 165
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals 165
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. 149
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 149
Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis 147
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. 147
Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication. 146
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:a randomized controlled trial 139
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. 138
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. 137
A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation. 136
Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance 136
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents 136
Clinical implications of the hyperdynamic syndrome in cirrhosis. 135
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension 133
Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease 133
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 133
An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers 130
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial 129
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 127
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D. 126
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 126
Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients 126
Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. 125
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 124
Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects 122
Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. 121
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 121
AISF position paper on liver disease and pregnancy. 121
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 121
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 120
Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis 119
Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation 118
Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis 117
Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience 116
Hepatocellular carcinoma and direct-acting antivirals: A never ending story? 116
The impact of sustained virological response on clinical outcomes in compensated HCV cirrhosis: a prospective cohort study 115
Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy 115
The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance 115
Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model 113
Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation 113
The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis 112
Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference 112
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin 109
Coagulation and fibrosis in chronic liver disease. 107
Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study) 107
NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. 106
Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study 106
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 106
Histological subclassification of cirrhosis 105
Impact of Tips Preliver Transplantation for the Outcome Posttransplantation 104
Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis 104
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? 103
Implication of Normal Liver Enzymes in Liver Disease 102
Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis 101
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 100
Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients 100
Computer-Assisted Image Analysis of Liver Collagen: Relationship to Ishak Scoring and Hepatic Venous Pressure Gradient 99
Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. 98
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. 98
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. 98
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 97
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 97
RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. 96
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. 96
TACE versus TAE as therapy for hepatocellular carcinoma. 95
Models for non-alcoholic fatty liver disease: a link with vascular risk. 95
Critically ill patients with cirrhosis and low serum sodium. 95
Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis 94
CLINICAL COURSE OF NIMESULIDE-INDUCED LIVER INJURY 92
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. 91
HCV CLEARANCE AFTER PEG IFN PLUS RBV IMPROVES THE COURSE OF HCV CIRRHOSIS REGARDLESS OF PORTAL HYPERTENSION 90
Predictors of Re‐bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS) 90
Fibrosis in chronic viral hepatitis 89
Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication? 89
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). 89
Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy 88
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 88
Real life experiences in HCV management in 2018 87
HBV recurrence after HCV clearance on DAAs: Sometimes they come back 87
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication 87
Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. 86
Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis 84
Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? the REAL Experience 84
Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. 83
Hepassocin as a treatment for fulminant hepatic failure: will it translate from rats to human? 82
Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. 82
Is global elimination of HCV realistic? 82
Immunological alterations in hepatitis C virus infection 80
The impact of sustained virological response on clinical outcome in compensated HCV cirrhosis: a prospective cohort study 79
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. 79
LIVER RELATED EVENTS AND SURVIVAL IN PATIENTS WITH COMPENSATED HCV CIRRHOSIS: THE ROLE OF SUSTAINED VIROLOGICAL RESPONSE TO PEG-IFN BASED THERAPY AND PORTAL HYPERTENSION 77
Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy 77
Baveno VII – Renewing consensus in portal hypertension 77
Meccanismi immunologici e molecolari del danno epatico da farmaci 73
The risk of hepatocellular carcinoma in HBV cirrhosis is affected by polymorphisms of the MERTK gene 73
A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort 73
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 73
Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. 72
Totale 10.835
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.231
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.231
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019850 0 0 0 0 0 0 0 0 0 0 427 423
2019/20203.972 435 158 263 550 410 504 402 299 417 187 221 126
2020/20211.797 126 150 156 146 114 75 95 147 197 240 159 192
2021/20221.752 58 318 149 53 46 67 132 115 213 163 148 290
2022/20232.133 212 488 39 186 247 298 119 148 246 16 73 61
2023/2024782 39 106 82 55 80 226 102 48 18 24 2 0
Totale 13.040